Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) in Patients with Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Transplant Oncology".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 13
Special Issue Editors
Interests: stem cell; transplantation; cancer immunotherapy; hematology
Interests: stem cell; transplantation; autologous stem cell transplantation; allogenic; cancer immunotherapy; CAR T cells
Special Issue Information
Dear Colleagues,
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a pivotal therapeutic strategy in the management of hematologic malignancies.
Its therapeutic efficacy is largely attributed to the graft-versus-leukemia (GVL) effect, wherein donor-derived immune cells target residual malignant cells. Advances in donor selection—such as haploidentical transplantation and the use of alternative stem cell sources—alongside innovations in conditioning regimens, post-transplant immunosuppression, and graft-versus-host disease (GVHD) prophylaxis—such as post-transplant cyclophosphamide—have improved outcomes and expanded donor selection and transplant eligibility. Despite its potential, challenges persist, including graft-versus-host disease, infectious complications, transplant-related mortality, and relapse. This issue will cover updates on ongoing research aimed at refining patient selection, optimizing timing, and integrating new immunotherapeutic strategies to improve the balance between disease control and transplant-related toxicity.
Dr. Caterina Alati
Dr. Martina Pitea
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematopoietic stem cell
- hematologic malignancies
- transplantation
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
